The infusion of funds from the Greenebaum family will predominantly support pioneering faculty research at the University of Maryland School of Medicine (UMSOM), bolstering efforts to develop cutting-edge cancer therapies. A major focus will be on immunotherapies, particularly chimeric antigen receptor (CAR) T-cell therapies, which have revolutionized treatment paradigms in hematologic malignancies and are now being explored aggressively for efficacy against solid tumors. This strategy involves reprogramming a patient’s immune cells to recognize and eradicate cancer cells with heightened specificity, offering hope for treating cancers that have historically been resistant to conventional approaches.

Beyond therapeutic innovations, the endowment will also strengthen survivorship programs at UMGCCC. Emerging wearable technologies capable of continuous physiological monitoring will be integrated into patient care strategies to optimize quality of life for cancer survivors. Personalized supportive care, including tailored nutritional regimens and psychosocial resources, will form a crucial component in enhancing long-term outcomes and mitigating treatment-related toxicities. This holistic approach underscores the center’s commitment to not only prolong lives but also improve the lived experience of patients beyond their clinical treatment.

As UMGCCC prepares for a significant physical expansion with its relocation to the Stoler Center for Advanced Medicine scheduled for fall 2026, the family’s donation assumes added significance. The new facility’s lobby will bear the Greenebaum name, symbolizing their enduring impact on the institution. The Stoler Center will house state-of-the-art laboratories, patient care suites, and clinical trial infrastructure designed to facilitate seamless translational research and multidisciplinary collaboration, ultimately accelerating the bench-to-bedside delivery of novel therapies.

Michael Greenebaum, scion of the Greenebaum family and an influential philanthropist, articulated the familial dedication behind the gift. Marking the 30th anniversary of the original donation, he emphasized that the contribution empowers the center to meet the escalating demand for expert oncology care in Maryland and its surrounding regions. The family’s longstanding involvement exemplifies how philanthropy can catalyze scientific breakthroughs and foster comprehensive patient-centric cancer care.

The Greenebaum family’s involvement extends beyond financial support. Michael Greenebaum serves as Chair of the University of Maryland School of Medicine’s Board of Visitors and sits on the UMGCCC Board of Advisors. He is also the founder of the Maryland Half-Marathon & 5K, which has raised over $8 million for the center, demonstrating an innovative approach to community engagement in cancer fundraising. This multi-faceted participation underscores the synergistic relationship between leadership, philanthropy, and research advancement.

The foundational success story of Marlene Greenebaum’s battle with breast cancer is intertwined with pioneering research at UMGCCC. She benefited from treatment with an aromatase inhibitor, a type of hormone therapy developed by Angela Brodie, PhD, a leading breast cancer researcher associated with the cancer center. Aromatase inhibitors function by blocking the enzyme aromatase, which converts androgens to estrogens, thereby reducing estrogen levels that fuel hormone receptor-positive breast cancers. This therapeutic breakthrough has become a standard of care globally, emblematic of how translational science at academic centers can alter clinical practices.

Leadership at UMGCCC recognizes the critical importance of sustained philanthropic support. Dr. Taofeek K. Owonikoko, the center’s Executive Director, noted that continuous funding is imperative for maintaining the momentum of clinical trials, which now number over 450 and represent a doubling from earlier years. These trials explore next-generation agents, combination immunotherapies, precision oncology approaches, and modalities aimed at overcoming tumor microenvironment-mediated resistance pathways. Such a robust clinical pipeline positions the center as a leader in oncology innovation.

UMGCCC’s research budget exceeds $130 million annually, reflecting its stature as a premier academic and research institution. The breadth of oncology clinical and basic research encompasses molecular biology, genomics, immunology, bioinformatics, and population health studies. The center’s faculty conduct extensive investigations into tumor biology, mechanisms of metastasis, and the development of novel biomarkers to enable early detection and therapeutic responsiveness. This comprehensive research spectrum embodies a systems biology approach to conquering cancer’s complexity.

The clinical environment benefits enormously from integration with UMGCCC’s basic science enterprises. The reciprocal relationship facilitates rapid hypothesis testing and functional validation of emerging targets in vivo through patient-derived xenograft models and organoid cultures. Moreover, the multidisciplinary teams comprising oncologists, surgeons, radiologists, pathologists, and data scientists collaborate intensively to tailor individualized treatment regimens, reinforcing the precision medicine paradigm.

Maryland’s University of Maryland Medical Center (UMMC), the flagship hospital in the 11-hospital University of Maryland Medical System (UMMS), serves as the clinical anchor for UMGCCC. UMMC’s advanced infrastructure supports high-complexity procedures, including solid organ transplantation and sophisticated imaging modalities vital for cancer diagnosis and management. The integration of clinical care and research fosters an ecosystem that translates scientific discoveries swiftly into standard practice, benefiting thousands of patients annually.

The upcoming expansion into the Stoler Center also represents a strategic bet on the future of oncology, emphasizing seamless integration of digital health technologies, telemedicine capabilities, and patient navigation services to improve access and adherence to cancer care protocols. The center’s mission aligns with global efforts to reduce cancer mortality through innovation while addressing survivorship challenges in an aging population that increasingly confronts late effects of cancer treatment.

In conclusion, the recent $5.5 million gift from the Marlene and Stewart Greenebaum Family Foundation marks a significant milestone for the University of Maryland Greenebaum Comprehensive Cancer Center. This philanthropic investment supports transformative cancer research, accelerates development of breakthrough therapies like CAR T-cell treatment for solid tumors, and enhances survivorship programs through advanced wearable technologies and tailored clinical support. The planned move to the Stoler Center for Advanced Medicine will bolster these efforts, situating UMGCCC to remain at the vanguard of cancer care and research. The Greenebaum family’s enduring legacy continues to inspire scientific innovation and exceptional patient care, reaffirming the profound impact of philanthropy in advancing the fight against cancer.

Subject of Research: Cancer research and treatment innovations at the University of Maryland Greenebaum Comprehensive Cancer Center, including immunotherapies and survivorship care.

Article Title: University of Maryland Greenebaum Comprehensive Cancer Center Receives $5.5 Million Gift to Accelerate Cancer Research and Care Expansion

News Publication Date: Not specified in the source content.

Web References:

• https://www.umms.org/umgccc
• https://www.umms.org/about/leadership/mohan-suntha
• https://www.medschool.umaryland.edu/profiles/gladwin-mark/
• https://www.umms.org/ummc/about/leadership/bert-w-omalley
• https://www.umms.org/find-a-doctor/profiles/dr-taofeek-kunle-owonikoko-md–phd-1578770871
• https://www.umms.org/ummc/about/leadership/heather-culp
• https://www.medschool.umaryland.edu/
• http://www.umm.edu/
• http://www.umms.org/

Image Credits: University of Maryland School of Medicine

Keywords: Cancer research, Immunotherapy, CAR T-cells, Survivorship care, Philanthropy, University of Maryland Greenebaum Comprehensive Cancer Center, Translational medicine, Clinical trials, Oncology innovation, Comprehensive cancer center

The crux of the study lies in its unprecedented scope, encompassing 256 patients diagnosed with five distinct hematologic cancers and enrolled across 13 different clinical trials. Such a robust patient cohort, coupled with data drawn from multiple cancer indications, provides a rare opportunity to discern universal biomarkers that transcend individual disease boundaries. Historically, the variability in data collection methodologies and limited sample sizes have hampered efforts to apply machine learning and informatics comprehensively in this field. The researchers have circumvented these barriers by harmonizing diverse datasets collected under a unified framework, enabling meaningful computational analyses and model building.

One of the study’s crowning technical achievements involves the deep phenotyping of T cells prior to infusion. Using flow cytometry, the team examined over two million apheresis-derived T cells, assessing expression patterns of 17 unique surface markers. This level of cellular resolution offers invaluable insights into the pre-treatment immune landscape, critical for understanding the intrinsic qualities that predict durable responses following CAR engineering and expansion. Such cellular immunoprofiling contrasts starkly with traditional bulk biomarker assessments and elevates the granularity of predictive models.

Beyond phenotypic characterization, the study also meticulously tracked the ex vivo expansion kinetics of CAR T cells during manufacture. This parameter is vital, as the manufacturing process itself can shape therapeutic efficacy and durability. Monitoring T-cell proliferation profiles across hundreds of samples captures a facet of cellular fitness and replicative potential that may influence in vivo persistence and tumor eradication. Integrating this dynamic manufacturing data with patient-specific immune phenotypes represents a sophisticated multidimensional approach not previously realized at such scale.

Perhaps equally impressive is the extensive quantification of soluble serum factors, with over 90,000 measurements spanning 30 different serum markers taken at multiple time points. These circulating biomarkers provide a window into systemic immunomodulatory states, inflammation levels, and tissue microenvironmental conditions that interplay with CAR T-cell activity. By serially sampling these markers, the researchers could deduce temporal patterns correlating with response kinetics, resistance mechanisms, and potential toxicities, offering a comprehensive temporal biomarker catalogue.

Additionally, the team employed quantitative PCR (qPCR) to serially track circulating CAR T cells post-infusion—a technique essential for understanding the pharmacodynamics and in vivo kinetics of the therapy. Capturing these longitudinal data points complements the pre-infusion and manufacturing snapshots, providing a holistic view of the therapy timeline from T-cell harvesting to eventual patient outcomes. This integration of serial molecular tracking further enhances the predictive accuracy of the biomarker models.

The fusion of this vast, heterogeneous data into sophisticated machine learning algorithms underpins the study’s innovative edge. By leveraging these computational tools, the investigators identified biomarker signatures that are predictive of not only therapeutic response but also of non-response, thus illuminating mechanisms of resistance and avenues to overcome them. The ability to pinpoint such pan-cancer biomarkers suggests that underlying immunological and cellular principles govern CAR T-cell efficacy broadly across hematologic malignancies.

Importantly, this work addresses a critical bottleneck in the field: the lack of generalizable predictive biomarkers that remain consistent across diverse cancer types and treatment contexts. Prior studies have often focused narrowly on single indications or employed inconsistent methodologies, limiting the translatability of findings. The pan-cancer, multi-trial approach adopted here provides a blueprint for future biomarker discovery initiatives, emphasizing the value of data harmonization and collaborative frameworks.

Clinically, these findings could herald a new era of personalized CAR T-cell therapy. By prospectively assessing these identified biomarkers in patients, clinicians might better stratify individuals likely to benefit from therapy, tailor manufacturing protocols, and design combination approaches to mitigate resistance. Such predictive capabilities would not only optimize outcomes but potentially reduce the severe toxicities and costs associated with ineffective treatments.

The study also underscores the growing synergy between immunotherapy and computational biology. With the application of machine learning to large immunological datasets, complex patterns and interdependencies emerge, which elude traditional statistical methods. These insights can refine mechanistic understanding of CAR T-cell dynamics, inform next-generation engineering strategies, and drive hypothesis-driven clinical trials.

Moreover, the implications extend beyond hematologic cancers. The methodological framework—integrating immunophenotyping, manufacturing analytics, serum biomarker profiling, and molecular tracking—can be adapted for solid tumors and other forms of adoptive cell therapies. As the CAR T-cell field expands into new oncologic disciplines, such comprehensive biomarker strategies will be vital for guiding rational therapy development.

The convergence of technological innovation, computational sophistication, and clinical breadth epitomized by this study signals a maturation of CAR T-cell research. By systematically capturing and analyzing millions of cellular, molecular, and clinical data points, the investigators have illuminated fundamental principles governing immunotherapeutic success and failure. Their pan-hematologic biomarker discoveries are a beacon for future translational applications, potentially transforming cancer treatment paradigms.

In the coming years, expanding these biomarker findings into prospective validation cohorts and integrating them with emerging omics datasets—including single-cell RNA sequencing and spatial transcriptomics—could further deepen insight. The continuous refinement and clinical deployment of such predictive tools promise to enhance patient selection, reduce adverse events, and ultimately improve long-term survival rates for a vast array of blood cancers.

This landmark study not only propels the science of CAR T-cell therapy forward but also exemplifies the power of interdisciplinary collaboration. It melds cutting-edge immunology, proteomics, genomics, and computational science to solve real-world clinical challenges. As immunotherapy moves closer to universal applicability, such holistic investigations are essential to unlocking its full therapeutic potential across cancer types.

While challenges remain—such as standardizing biomarker assays for clinical use, understanding the influence of tumor microenvironments, and addressing rare resistant phenotypes—the study’s findings provide a roadmap for overcoming these hurdles. The promise of predictive biomarkers is no longer a distant objective but an achievable goal within grasp, thanks to efforts like this that harness the vast complexity of cancer biology.

Ultimately, by assembling a large, diverse patient cohort and applying rigorous, integrative analyses, the researchers have redefined the biomarker landscape of CAR T-cell therapy. Their work offers hope for more precise, effective, and safe cancer immunotherapies, marking a significant milestone in the fight against hematologic malignancies and beyond.

Subject of Research: Predictive biomarkers in chimeric antigen receptor (CAR) T-cell therapy for pan-hematologic cancers.

Article Title: Predictive biomarkers of response to chimeric antigen receptor (CAR) T-cell therapy for pan-haematologic cancer.

Article References:
Chen, G.M., Jain, A., Gering, D.T. et al. Predictive biomarkers of response to chimeric antigen receptor (CAR) T-cell therapy for pan-haematologic cancer. Nat. Biomed. Eng (2026). https://doi.org/10.1038/s41551-026-01633-7

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41551-026-01633-7